Specifically, the overall mortality was 4 of 33 (12.1%) in TERT hypermethylated patients versus 16 of 538 (3.0%) in TERT hypomethylated patients (P=0.023); disease specific mortality was 3 of 32 (9.4%) in TERT hypermethylated patients versus 7 of 533 (1.3%) in TERT hypomethylated patients (P=0.015); tumor recurrence was 4 of 19 (21.1%) in TERT hypermethylated patients versus 27 of 381 (7.1%) in TERT hypomethylated patients (P=0.050); disease progression was observed in 9 of 33 (27.3%) TERT hypermethylated patients versus 56 of 538 (10.4%) TERT hypomethylated patients (P=0.003). The gene discussed is TERT; the disease is neoplasm.